# Gingivitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/gingivitis

> 2 upcoming FDA catalysts in gingivitis: silica free meridol (CL) on April 2027 (primary completion); silica free meridol (CL) on Apr to Jul 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 30, 2025 | [Periguard regimen primary completion](https://sec-api.dev/pdufa/periguard-regimen) | CL | Gingivitis | completed | "NCT07210138 (Clinical Investigation of PerioGard (Test) Regimen): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07210138)) |
| April 2027 | [Silica free meridol primary completion](https://sec-api.dev/pdufa/silica-free-meridol) | CL | Gingivitis | scheduled | "NCT07842978 (Clinical Study Examining the Control of Plaque and Gingivitis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07842978)) |
| Apr to Jul 2027 | [Silica free meridol topline data readout](https://sec-api.dev/pdufa/silica-free-meridol) | CL | Gingivitis | scheduled | "NCT07842978 (Clinical Study Examining the Control of Plaque and Gingivitis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07842978)) |

## Drugs

- [Periguard regimen](https://sec-api.dev/pdufa/periguard-regimen) (CL)
- [Silica free meridol](https://sec-api.dev/pdufa/silica-free-meridol) (CL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/gingivitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Gingivitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/gingivitis

```bibtex
@misc{secapidev_indications_gingivitis_20261116,
  title        = {Gingivitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/gingivitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_gingivitis_20261116","title":"Gingivitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/gingivitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
